OakChart

iBio Inc

IBIOHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

0.8242+0.0442 (5.67%)
2026-11-12 06:46 CET
Market cap
50.16 USD m
Revenue, TTM
1.07 USD m
Net income, TTM
-34.88 USD m
Free cash flow, TTM
-27.59 USD m
EPS diluted, TTM
-0.40
P/E
-
Compare

Price

IBIO against its 20, 50 and 200-day averages
2050200beatmiss
Patternshover a marker to name it
1.001.502.002.5M5.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IBIOclose 0.8220-day 0.7850-day 1.00200-day 1.630.8252w low

78.4% under the 52-week high of 3.82 on 10 Dec 2025. 52-week low 0.69 on 26 Oct 2026. Last 15 sessions, 23.9% high to low

Volume 0.52× normal · the line is the 50-bar volume average

Profile

IBIO
52-week range, 4% of the way up
0.693.82

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

Employees23
IPOAug 19, 2008
Beta1.47
ATR, 14d0.07
Rel volume0.52
Short float7.25%
Insider own8.54%
Inst own64.35%

Snapshot

6 groups

Valuation

Index-
Market Cap50.16M
Enterprise Value-24.42M
Income-34.88M
Sales1.07M
Book/sh1.22
Cash/sh1.26
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees23
IPOAug 19, 2008

Ratios

P/E-
Forward P/E-
PEG-
P/S46.88
P/B0.67
P/C0.65
P/FCF-
EV/EBITDA-
EV/Sales-22.82
Quick Ratio9.48
Current Ratio9.48
Debt/Eq0.03
LT Debt/Eq0.02
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.40
EPS next Y-0.54
EPS next Q-0.09
EPS this Y-6.25%
EPS next Y-60.00%
EPS next 5Y-25.46%
EPS past 3/5Y85.59% 64.94%
Sales past 3/5Y- -46.91%
EPS Y/Y TTM71.61%
Sales Y/Y TTM115.00%
EPS Q/Q53.89%
Sales Q/Q975.00%
EarningsNov 10 AMC
EPS/Sales Surpr.28.57% 4300.00%

Ownership

Insider Own8.54%
Insider Trans0.00%
Inst Own64.35%
Inst Trans16.11%
ROA-45.65%
ROE-51.82%
ROIC-43.55%
Gross Margin7.63%
Oper. Margin-3025.58%
Profit Margin-3244.19%
SMA205.51%
SMA50-17.66%
SMA200-49.58%
Trades-

Technical

Shs Outstand64.31M
Shs Float55.66M
Short Float7.25%
Short Ratio5.75
Short Interest4.03M
52W High3.82 -78.42%
52W Low0.69 20.16%
Volatility8.87% 8.65%
ATR (14)0.07
RSI (14)46.77
Beta1.47
Rel Volume0.52
Avg Volume701.94K
Volume361,872

Performance

Perf Week3.02%
Perf Month5.42%
Perf Quarter-41.13%
Perf Half Y-46.83%
Perf YTD-57.30%
Perf Year-33.53%
Perf 3Y-85.10%
Perf 5Y-99.79%
Perf 10Y-99.96%
Recom1.12
Target Price5.53
Prev Close0.78
Price0.82
Change %5.67%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Sep 17, 2026InitiatedHH.C. WainwrightBuy$7+749.3%
Jun 08, 2026InitiatedRRaymond JamesOutperform$5+506.6%
Jun 05, 2026InitiatedRB. Riley SecuritiesBuy$6+628.0%
Oct 21, 2025InitiatedOOppenheimerOutperform$5+506.6%
Oct 17, 2025InitiatedLLeerink PartnersOutperform$2+142.7%
May 28, 2024InitiatedCChardan Capital MarketsBuy$5+506.6%
Nov 29, 2021InitiatedJJMP SecuritiesMkt Outperform$1.50+82.0%
Jan 22, 2021InitiatedCCantor FitzgeraldOverweight$3+264.0%
Jun 26, 2020InitiatedAAlliance Global PartnersBuy$2.55+209.4%

Peers

Mkt cap
TickerCompanyMkt cap
KROSKeros Therapeutics Inc187.22M
SRRKScholar Rock Holding Corp5.68B
VERUVeru Inc36.49M
ABSIAbsci Corp1.74B
ABCLAbCellera Biologics Inc3.90B
BMEABiomea Fusion Inc44.28M
CRBPCorbus Pharmaceuticals Holdings Inc77.36M
ALTAltimmune Inc375.41M
SEPNSepterna Inc2.31B
XBITXBiotech Inc59.45M

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Banjak MarcChief Legal OfficerMar 26 '26Buy1.6513,93423,05525,000Mar 27 04:05 PM
Duran FelipeChief Financial OfficerMar 19 '26Buy2.0224,83550,13235,974Mar 23 07:31 AM
Brenner MartinSee RemarksMar 19 '26Buy2.0212,33624,91930,652Mar 23 07:30 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200
  • iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update (GlobeNewswire) +5.67%
  • iBio to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610's Potential to Preserve Muscle in Combination with GLP-1 Therapy (GlobeNewswire) -13.44%
  • iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference (GlobeNewswire)
  • iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer (GlobeNewswire)
  • iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study (GlobeNewswire)
  • iBio to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire) -6.88%
  • iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity (GlobeNewswire)
  • iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors (GlobeNewswire)
  • iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia (GlobeNewswire) +6.16%
  • iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire)
  • iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2027Q12026-11-10-0.050-0.070-0.0501.100.035
2026Q42026-08-28-0.050-0.069-0.1900.000.008
2026Q32026-05-12-0.070-0.063-0.0650.000.026
2026Q22026-02-10-0.090-0.140-0.0910.000.053
2026Q12025-11-12-0.110-0.207-0.1080.100.033
2025Q42025-09-05-0.320-0.350-0.3140.200.102
2025Q32025-05-02-0.490-0.320-0.4930.000.102
2025Q22025-02-10-0.480-0.460-0.4780.200.002
2025Q12024-11-12-0.460-0.460-0.4620.000.001
2024Q42024-09-20-0.380-0.470-0.9020.180.002
2024Q32024-05-13-0.710--0.8540.00--
2023Q32023-07-31-10.800--11.0650.20-1
2023Q22023-05-04-68.400--68.4270.00-2
2023Q12022-11-23-41.000-507.5-41.0100.060.602
2022Q42022-09-27-42.500-32.500-39.0850.100.252
2022Q32022-05-12-30.000-27.500-28.4051.940.202

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2013FY-650--6501.01-
2020FY-305-310-304.641.640.60
2021FY-60.000-80.000-59.9802.372.60
2022FY-115.3-105-2,8892.402.55
2024FY-4.030-7.410-6.5010.230.03
2025FY-1.750-1.760-1.7500.400.30
2026FY-0.320-0.331-0.2950.100.10
2027FY--0.340--0.63
2028FY--0.544--0.22
2029FY--0.632--0.37
2030FY--0.870--0.05
2031FY--0.850---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2027Q2S2026-11-115000.000.000.00
2027Q2S2026-11-104000.000.000.00
2027Q2S2026-10-084000.000.000.00
2027Q2S2026-09-165000.000.000.00
2027Q2S2026-08-284000.000.000.00
2027Q2S2026-08-273000.000.000.00
2027Q2S2026-05-132000.000.000.00
2027Q2S2026-02-212000.000.000.00
2027Q2S2026-02-113000.000.000.00
2027Q2S2025-12-041000.000.000.00
2027Q2S2025-11-132000.000.000.00
2027Q2S2025-11-122000.000.000.00
2027Q2S2025-11-112000.000.000.00
2027Q2S2025-11-102000.000.000.00

Estimate history

EPS, annual-770-471.655-304.64-59.98-2889.06-106.182-6.501-1.75-0.318-0.3955
Period201820192020202120222023202420252026TTM
EPS, quarterly-0.462-0.478-0.493-0.314-0.108-0.091-0.065-0.19-0.05
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27
Sales, annual0.4442.0181.6382.3711.88400.2250.40.11.07
Period201820192020202120222023202420252026TTM
Sales, quarterly00.200.20.10001.075
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27
Shares, annual0.0320.040.280.4360.0171.0168.62419.34955.69964.307
Period201820192020202120222023202420252026MRQ
Shares, quarterly8.6389.16810.06619.34920.25530.05334.54455.69964.307
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue1.070.100.400.230.001.882.371.642.02
Cost of Goods Sold Incl. D&A0.991.031.131.251.113.793.882.94-
Gross Profit0.08-0.93-0.73-1.02-1.11-1.91-1.50-1.31-
Selling, General and Administrative Excl. Other32.6129.2117.8815.6127.6727.7929.6112.7015.88
Research and Development22.7419.648.315.1810.339.839.993.575.47
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-32.52-30.14-18.60-16.63-28.78-29.70-31.11-14.00-15.61
Interest Expense-0.050.210.170.081.412.452.471.90
Unusual Expense5.005.000.000.000.560.000.000.000.18
Net Income Before Taxes-34.88-33.04-18.38-15.44-29.31-29.51-23.21-16.44-17.60
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-34.88-33.04-18.38-15.44-29.31-29.51-23.21-16.44-17.60
Net Income From Continuing Operations-34.88-33.04-18.38-15.44-29.31-29.51-23.21-16.44-17.59
Net Income-34.88-33.04-18.38-24.91-65.01-50.39-23.47-38.26-17.85
EPS (Recurring)-0.21-0.28-1.75-6.50-105.54-2,889.06-59.98-304.64-468.34
EPS (Basic, Before Extraordinaries)-0.40-0.32-1.75-6.50-106.18-2,889.06-59.98-304.64-471.65
EPS (Diluted)-0.40-0.32-1.75-6.50-106.18-2,889.06-59.98-304.64-471.65
EBITDA-31.53-29.11-17.48-15.38-27.67-25.91-28.70-11.76-13.86
Non-Operating Income (Expense)2.722.150.441.360.120.1810.350.030.09
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.491.371.531.982.863.961.590.390.24
Price To Sales Ratio166.381,821.0520.0335.93-1.22124.5885.116.64
Gross Margin7.63-930.00-181.50-455.56--101.22-63.48-79.73-
Operating Margin-3,025.58-30,138.00-4,650.50-7,392.89--1,576.27-1,312.15-854.88-773.49
Net Margin-3,244.19-33,044.00-4,594.25-11,069.78--2,674.68-989.75-2,335.78-884.69
Shares Outstanding64.3155.7019.358.621.020.020.440.280.04
Market Capitalization50.1650.1612.3818.2012.3957.60328.99310.9613.88

Income statement, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q42025Q32025Q2
Total Revenue1.070.000.000.000.100.200.000.20
Cost of Goods Sold Incl. D&A0.250.250.250.240.290.280.280.28
Gross Profit0.82-0.25-0.25-0.24-0.19-0.09-0.28-0.08
Selling, General and Administrative Excl. Other9.1611.135.616.705.765.114.604.34
Research and Development6.658.563.254.283.553.221.911.88
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-8.34-11.38-5.86-6.95-5.95-5.20-4.88-4.42
Interest Expense0.00-0.020.040.040.040.050.06
Unusual Expense0.000.002.502.500.000.000.000.00
Net Income Before Taxes-7.55-10.60-7.73-8.99-5.72-5.16-4.86-4.36
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-7.55-10.60-7.73-8.99-5.72-5.16-4.86-4.36
Net Income From Continuing Operations-7.55-10.60-7.73-8.99-5.72-5.16-4.86-4.36
Net Income-7.55-10.60-7.73-8.99-5.72-5.16-4.86-4.36
EPS (Recurring)-0.05-0.19-0.05-0.07-0.11-0.31-0.49-0.48
EPS (Basic, Before Extraordinaries)-0.05-0.19-0.06-0.09-0.11-0.31-0.49-0.48
EPS (Diluted)-0.05-0.19-0.06-0.09-0.11-0.31-0.49-0.48
EBITDA-8.09-11.13-5.61-6.70-5.66-4.91-4.60-4.14
Non-Operating Income (Expense)0.790.780.660.490.270.080.070.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.430.420.380.250.320.270.370.47
Price To Sales Ratio166.38974.72757.47637.7687.7231.33105.7259.66
Gross Margin76.56----189.00-42.50--40.50
Operating Margin-775.63----5,951.00-2,599.00--2,209.50
Net Margin-702.42----5,720.00-2,581.50--2,182.00
Shares Outstanding64.3155.7034.5430.0520.2519.3510.079.17
Market Capitalization50.1686.9465.6343.4016.2712.3839.7022.42

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments88.048.5814.217.3333.5296.9755.114.4215.93
Short Term Receivables1.100.100.710.206.105.535.620.100.07
Inventories0.000.000.000.000.000.030.800.000.00
Other Current Assets3.081.030.7518.735.452.070.210.290.28
Total Current Assets92.229.7215.6726.2645.07104.6061.754.8116.29
Net Property, Plant & Equipment4.755.286.377.554.4434.7431.2724.3825.15
Total Investments and Advances0.230.210.210.256.000.000.000.000.00
Long-Term Note Receivable0.001.101.081.711.636.660.00--
Intangible Assets1.826.855.375.394.850.951.141.371.62
Other Assets0.080.030.030.0537.420.020.020.020.03
Total Assets99.1123.1828.7341.2199.41146.9794.1930.5943.08
Short Term Debt Incl. Current Port. of LT Debt0.551.310.9513.6022.250.970.560.210.20
Accounts Payable4.422.190.361.854.262.251.761.000.79
Income Tax Payable--0.000.270.28----
Other Current Liabilities6.782.612.535.873.643.422.922.241.05
Total Current Liabilities11.746.113.8421.5830.446.645.243.462.04
Long Term Debt1.652.203.513.483.5131.7532.3524.6724.88
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.060.771.970.000.000.000.00
Total Liabilities13.408.307.4125.8335.9238.4037.5828.1326.92
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity85.7114.8821.3215.3863.48108.5856.622.4616.17
Total Shareholders Equity85.7114.8821.3215.3863.48108.5856.622.4616.17
Accumulated Minority Interest0.000.000.000.000.00-0.02-0.01-0.01-0.00
Total Equity85.7114.8821.3215.3863.48108.5756.612.4616.16
Total Liabilities & Stockholders Equity99.1123.1828.7341.2199.41146.9794.1930.5943.08
Book Value Per Share1.540.772.4715.153,637.21249.19202.1061.11503.92
Tangible Book Value Per Share1.510.421.859.843,359.28247.01198.0227.02453.43
Full-Time Employees2320192610575515554
Price to Book Ratio0.670.670.720.810.913.035.492.012.51
Return on Assets-54.04-70.79-44.16-41.69-23.96-19.25-26.35-47.76-40.72
Return on Equity-65.70-101.52-84.15-74.33-34.30-28.10-55.65-188.88-128.43
Return on Invested Capital-37.82-107.60-100.31-344.75-75.08-16.54-18.48-64.84-39.23
Quick Ratio7.851.594.081.221.4815.7411.641.398.00
Current Ratio7.851.594.081.221.4815.7411.791.398.00

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-34.88-33.04-18.38-24.91-65.01-50.30-23.21-16.44-17.60
Depreciation0.991.031.131.251.383.792.412.241.75
Other Funds (Non Cash)6.356.271.478.2727.305.471.890.390.42
Funds from Operations-27.53-25.74-15.78-15.39-36.33-41.05-18.91-13.81-15.43
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.592.520.48-3.175.873.24-11.150.471.45
Cash from Operating Activities-26.94-23.22-15.30-18.55-30.46-37.80-30.06-13.35-13.97
Capital Expenditures-1.40-0.58-0.02-0.21-6.43-11.63-5.16-1.15-0.99
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.010.000.000.122.600.000.000.00-
Purchase or Sale of Investments-31.11-31.500.000.0010.846.50-19.820.000.00
Purchase of Investments-47.81-42.300.000.000.00-7.12-23.820.000.00
Sale Or Maturity of Investments16.7010.800.000.0010.8413.624.000.000.00
Other Uses21.460.000.000.000.000.00-1.500.000.00
Other Sources0.080.070.761.000.000.000.000.00-
Cash from Investing Activities-10.96-32.000.740.917.01-5.13-26.48-1.15-0.99
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock61.70109.589.7025.4311.490.0873.6266.653.65
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock61.70109.589.7025.4311.490.0873.6266.653.65
Proceedsfrom Stock Options5.603.539.5725.4311.490.0073.5660.193.65
Issuance or Reduction of Debt, Net-6.47-6.63-0.77-1.14-9.12-5.83-0.33-1.46-0.20
Change in Long Term Debt-0.61-0.77-0.48-1.95-9.12-5.83-0.33-1.46-0.20
Issuance of Long Term Debt0.000.000.000.000.500.000.000.600.00
Reduction of Long Term Debt-0.61-0.77-0.48-1.95-9.62-5.83-0.33-2.06-0.20
Net Financing Active Other Cash Flow0.000.100.000.20-0.04-0.055.550.000.00
Other Financing Activities Uses0.000.000.00-0.01-0.04-0.050.000.000.00
Cash from Financing Activities55.22103.058.9324.492.32-5.8078.8365.193.45
Exchange Rate Effect---0.000.030.00-0.00-0.00-0.00
Net Change in Cash17.3247.83-5.636.85-21.09-48.7322.2950.69-11.51
Free Cash Flow-27.59-23.80-15.32-18.76-36.89-45.13-34.98-14.42-14.89
Preferred Dividends (Cash Flow)-0.000.000.000.00----
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q4
Cash & Short Term Investments76.6588.0474.8052.7049.578.58
Short Term Receivables1.251.100.000.000.070.10
Inventories0.000.000.000.000.000.00
Other Current Assets3.343.082.450.671.141.03
Total Current Assets81.2492.2277.2553.3750.779.72
Net Property, Plant & Equipment4.594.755.085.315.175.28
Total Investments and Advances0.230.230.230.230.230.21
Intangible Assets2.571.821.834.346.846.85
Other Assets0.030.080.290.010.030.03
Total Assets88.6599.1185.8364.3964.1623.18
Short Term Debt Incl. Current Port. of LT Debt0.560.550.530.521.231.31
Accounts Payable4.414.423.042.652.822.19
Other Current Liabilities3.606.782.942.732.002.61
Total Current Liabilities8.5711.746.505.906.056.11
Long Term Debt1.511.651.791.932.072.20
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities10.0813.408.307.838.128.30
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity78.5785.7177.5456.5656.0414.88
Total Shareholders Equity78.5785.7177.5456.5656.0414.88
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity78.5785.7177.5456.5656.0414.88
Total Liabilities & Stockholders Equity88.6599.1185.8364.3964.1623.18
Book Value Per Share1.221.542.241.882.770.77
Tangible Book Value Per Share1.181.512.191.742.430.42
Full-Time Employees-23---20
Price to Book Ratio0.670.781.010.701.080.67
Return on Assets-45.65-54.04-52.61-57.47-45.35-70.79
Return on Equity-51.82-65.70-62.09-70.22-54.50-101.52
Return on Invested Capital-9.43-12.13-9.74-15.37-9.84-30.23
Quick Ratio9.487.8511.889.048.391.59
Current Ratio9.487.8511.889.048.391.59

Cash flow, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q4
Net Income-7.55-10.60-7.73-8.99-5.72-5.16
Depreciation0.250.250.250.240.290.28
Other Funds (Non Cash)0.380.472.792.720.290.26
Funds from Operations-6.92-9.88-4.69-6.03-5.14-4.62
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.463.65-1.390.79-0.530.01
Cash from Operating Activities-9.39-6.23-6.08-5.24-5.67-4.62
Capital Expenditures-0.85-0.02-0.01-0.52-0.03-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.010.000.000.000.000.00
Purchase or Sale of Investments0.39-31.500.000.000.000.00
Purchase of Investments-5.51-42.300.000.000.000.00
Sale Or Maturity of Investments5.9010.800.000.000.000.00
Other Uses0.0032.43-8.50-2.47-21.460.00
Other Sources0.00-5.335.400.000.000.05
Cash from Investing Activities-0.45-4.41-3.11-2.98-21.490.04
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-1.1225.2628.159.4046.768.44
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-1.1225.2628.159.4046.768.44
Proceedsfrom Stock Options-1.175.711.26-0.19-3.258.44
Issuance or Reduction of Debt, Net0.00-5.860.00-0.61-0.16-0.26
Change in Long Term Debt0.000.000.00-0.61-0.16-0.12
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-0.61-0.16-0.12
Net Financing Active Other Cash Flow0.000.000.000.000.100.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-1.1219.4028.158.7946.708.18
Net Change in Cash-10.968.7618.960.5619.553.61
Free Cash Flow-9.49-6.25-6.09-5.76-5.70-4.62

Revenue breakdown

Pharmaceutical Preparations2025: 400.00K 2026: 100.00K
United States2025: 400.00K 2026: 100.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.25%4.0M55.7M708.94K
2026-10-156.71%3.7M55.7M735.74K
2026-09-307.55%4.2M55.7M772.41K
2026-09-158.87%4.9M55.7M812.43K
2026-08-319.35%5.2M55.7M857.32K
2026-08-1411.06%5.0M45.4M832.14K
2026-07-3111.10%5.1M46.0M921.30K
2026-07-1511.71%5.4M46.0M979.88K
2026-06-3010.20%4.7M46.0M850.78K
2026-06-158.16%3.8M46.0M912.86K
2026-05-298.17%3.8M46.0M944.94K
2026-05-157.41%3.4M46.0M1.01M
2026-04-3010.21%3.4M33.5M1.05M
2026-04-1510.88%3.6M33.5M1.05M
2026-03-3113.89%4.2M30.1M1.78M
2026-03-1313.94%4.2M30.1M1.85M
2026-02-2713.08%3.9M30.1M5.75M
2026-02-1313.91%4.2M30.1M5.73M
2026-01-3019.56%3.9M19.7M5.83M
2026-01-1519.77%3.9M19.7M8.03M

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-10-198-KCurrent report2026-10-14SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-14SCHEDULE 13GSEC
2026-10-138-KCurrent report2026-10-13SEC
2026-09-148-KCurrent report2026-09-14SEC
2026-09-04ARSAnnual report to security holders. 2026-06-30SEC
2026-09-04DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-04SEC
2026-08-2810-KAnnual report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-288-KCurrent report2026-08-28SEC
2026-08-20PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-14SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-048-KCurrent report2026-07-31SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-08-043Initial statement of beneficial ownership of securities2026-07-31SEC
2026-07-178-KCurrent report2026-07-17SEC
2026-07-018-KCurrent report2026-07-01SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-18SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-153Initial statement of beneficial ownership of securities2026-05-07SEC
2026-05-15SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-0398.11K300
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Affinity Asset Advisors, LLC8.07%
SILVERARC CAPITAL MANAGEMENT, LLC7.09%
Vestal Point Capital, LP5.23%
VANGUARD CAPITAL MANAGEMENT LLC4.22%
Frazier Life Sciences Management, L.P.3.93%
Ensign Peak Advisors, Inc3.69%
Woodline Partners LP3.58%
MILLENNIUM MANAGEMENT LLC3.32%
CITADEL ADVISORS LLC2.79%
BALYASNY ASSET MANAGEMENT L.P.2.36%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.95%
VANGUARD EXTENDED MARKET INDEX FUND1.17%
Fidelity Extended Market Index Fund0.52%
iShares Micro-Cap ETF0.21%
Fidelity Total Market Index Fund0.17%
Fidelity Series Total Market Index Fund0.15%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.06%
VANGUARD BALANCED INDEX FUND0.04%
Fidelity Nasdaq Composite Index Fund0.04%
1290 VT Micro Cap Portfolio0.01%

OakChart. IBIO. Cached 15 minutes.